Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E16.43 EPS (ttm)9.77 Insider Own0.20% Shs Outstand762.48M Perf Week-0.58%
Market Cap122.43B Forward P/E12.87 EPS next Y12.48 Insider Trans-2.33% Shs Float746.25M Perf Month-5.39%
Income7.43B PEG2.07 EPS next Q2.79 Inst Own81.00% Short Float1.11% Perf Quarter-6.12%
Sales22.47B P/S5.45 EPS this Y35.20% Inst Trans0.02% Short Ratio2.98 Perf Half Y2.70%
Book/sh40.12 P/B4.00 EPS next Y9.95% ROA10.10% Target Price189.41 Perf Year1.14%
Cash/sh45.95 P/C3.49 EPS next 5Y7.93% ROE25.90% 52W Range137.31 - 176.85 Perf YTD0.84%
Dividend4.00 P/FCF20.45 EPS past 5Y13.60% ROI12.50% 52W High-9.21% Beta1.09
Dividend %2.49% Quick Ratio3.70 Sales past 5Y7.60% Gross Margin81.40% 52W Low16.94% ATR2.39
Employees17900 Current Ratio4.00 Sales Q/Q5.90% Oper. Margin40.70% RSI (14)38.94 Volatility1.23% 1.43%
OptionableYes Debt/Eq1.10 EPS Q/Q14.90% Profit Margin33.10% Rel Volume1.20 Prev Close158.99
ShortableYes LT Debt/Eq0.93 EarningsOct 27 Payout36.30% Avg Volume2.79M Price160.57
Recom2.40 SMA20-1.90% SMA50-4.77% SMA2002.06% Volume3,334,500 Change0.99%
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Oct-27-16 07:12PM  Amgen tops Street 3rd-quarter profit and revenue forecasts
06:48PM  Amgen Inc. Delivers in Q3 Despite Sluggish Revenue at Motley Fool
05:06PM  Options Insight: How to Play Amgen
05:05PM  Options Insight: How to Play Amgen at Bloomberg
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today
04:58PM  Amgen 3rd-quarter profit tops Street view on cost cutting
04:36PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:19PM  Amgen beats profit expectations and raises its outlook at MarketWatch
04:16PM  Will Amgen (AMGN) Stock Be Helped by Q3 Beat, Guidance?
04:05PM  Amgen 3rd-quarter profit tops expectations on cost cutting
04:01PM  Amgen Reports Third Quarter 2016 Financial Results PR Newswire
03:46PM  11 improving health-care companies whose stocks are loved by analysts at MarketWatch
12:40PM  What to Watch When Amgen Reports Earnings
08:30AM  5 Stocks to Watch After the Market Closes Today
07:07AM  Q3 2016 Amgen Inc Earnings Release - Time Not Supplied
Oct-26-16 03:32PM  Amgen Invests in Israeli Digital Health Co. (AMGN) at Investopedia
12:23PM  Zacks: Amgen To Surpass Q3 Expectations (AMGN) at Investopedia
10:47AM  Biogen profit tops expectations; focus on CEO search, new drugs
09:43AM  Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates
08:54AM  Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales
08:45AM  Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More
08:31AM  Is a Surprise Coming for Amgen (AMGN) This Earnings Season?
07:15AM  Short Sellers Cant Make Up Their Minds on Major Biotechs at 24/7 Wall St.
Oct-25-16 04:29PM  3 Key Questions for Amgen Inc. in Q3 at Motley Fool
08:37AM  Merck Keytruda Gets FDA Approval for First-Line Lung Cancer
05:30AM  Amgen To Invest In Israel-Based eHealth Ventures PR Newswire
Oct-24-16 04:07PM  Index funds can be inferior to active funds in two crucial ways at MarketWatch
04:00PM  Amgen Announces Webcast Of 2016 Third Quarter Financial Results PR Newswire
11:30AM  Biosimilars May Pose a Threat to Roches Herceptin
10:28AM  Healthcare ETFs: Gain or Pain Ahead in Q3 Earnings?
Oct-23-16 10:35AM  Top Health Care Earnings Coming Next Week at 24/7 Wall St.
Oct-21-16 05:03PM  Sanders urges Californians to approve drug price ballot measure Reuters
10:47AM  Will Amgen (AMGN) Sustain its Earnings Beat Trend in Q3?
10:00AM  Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals
Oct-20-16 04:19PM  Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients PR Newswire
04:03PM  Amgen Partner Kite Not 'A One-Trick Pony'; Pipeline Grows In 2017
10:29AM  7 Drug Stocks to Consider as Biosimilars Pick Up Pace
09:58AM  Biotech Stocks: Do Earnings Even Matter Anymore? at
09:55AM  Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains at 24/7 Wall St.
08:05AM  What Biogen Is Doing that Put It in Good Favor with Analysts
Oct-19-16 09:07AM  3 Stocks to Supplement Your Social Security Benefits at Motley Fool
08:05AM  Why Vertex Lowered Its Guidance for Orkambi
Oct-18-16 12:06PM  [$$] J&J prepares for drug price war with Pfizer at Financial Times
09:41AM  Pfizer to Launch Remicade Biosimilar in U.S. in November
Oct-17-16 06:16PM  Pfizer to launch cheaper version of J&J immune drug Remicade
03:34PM  Amgen: Indicators Are Mixed, What Could Be Next?
10:21AM  Amgen to Pay $1 Per Share 4Q Dividend (AMGN) at Investopedia
Oct-16-16 12:56PM  High Pressure Economy Means Future-Focused Investing
Oct-14-16 04:32PM  Better Buy: Amgen Inc. vs. Gilead Sciences, Inc. at Motley Fool
04:10PM  AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:05PM  Amgen Announces 2016 Fourth Quarter Dividend PR Newswire
04:00PM  Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors PR Newswire
11:04AM  How Valeant Is Trying to Improve Its Profit Margins
Oct-13-16 01:45PM  19 Bay Area companies to watch at this year's S.F. BIO Investor event at
Oct-12-16 05:49PM  Martin Whitman's Top Recent Investments
12:15PM  Trading the biotech sell-off
11:09AM  Amgen, Inc. : AMGN-US: Dividend Analysis : August 17th, 2016 (record date) : By the numbers : October 12, 2016
07:10AM  Short Sellers Have Mixed Views on Major Biotechs at 24/7 Wall St.
Oct-11-16 05:59PM  Final Trade: AMGN, OLED, & more
05:15PM  Biotech bloodbath
04:59PM  Biotech Stocks Smacked For Biggest Decline in 3 1/2 Months at The Wall Street Journal
12:20PM  Amgen Reports Positive Cancer Drug Results (AMGN) at Investopedia
09:25AM  Teva Acquires Rights to Oncology Biosimilar Candidates
08:21AM  3 Top Biotech Stocks to Buy Right Now at Motley Fool
Oct-10-16 09:09AM  New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin PR Newswire
Oct-07-16 03:51PM  Following Kite Pharma's Positive Top-Line Data, Focus Turns To Commercial Outlook
12:22PM  6 Healthcare Stocks Investors Can't Miss in Q3 Earnings
11:51AM  Will Biogen Join Gilead in the Disappointment Club? at
10:36AM  Pfizer to Sell Hospira Infusion Unit to ICU Medical for $1B
09:11AM  3 Ways Rockwell Medical Inc. Could Turn Things Around at Motley Fool
Oct-06-16 06:50PM  Amgen Set To Appear at ESMO Congress (AMGN) at Investopedia
Oct-05-16 04:10PM  New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress PR Newswire
03:00PM  Amgen Inks Oncology, Neuroscience Deals (AMGN) at Investopedia
Oct-04-16 04:00PM  Amgen To Participate In Citi Biotech R&D Conference Call PR Newswire
09:53AM  Amgen Announces Publication of Blincyto Phase I/II Data
Oct-03-16 04:09PM  Study Results Published In Journal of Clinical Oncology Show BLINCYTO® (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Ly PR Newswire
03:13PM  3 Top Biotech Stocks to Buy in October at Motley Fool
01:07PM  Amgen Signs Agreement With Exosome Dignostics (AMGN) at Investopedia
11:05AM  $1.5B deal: AstraZeneca licenses experimental Crohn's disease drug to Allergan at
11:03AM  Gilead: Will New HIV Drugs Overshadow Hep C Worries? at
09:48AM  Friends or Foes: Amgen and Novartis (AMGN, NVS) at Investopedia
09:33AM  Amgen Expands New Drugs Into Indian Market (AMGN, RDY) at Investopedia
02:21AM  AstraZeneca licenses inflammatory disease candidate to Allergan Reuters
Oct-02-16 02:12PM  3 Healthcare Stocks That Could Raise Their Dividends at Motley Fool
05:00AM  Big Pharma vs Big Pharma in court battles over biosimilar drugs Reuters
Oct-01-16 01:15AM  Novartis psoriasis drug maintains efficacy after 4 years - study Reuters
Sep-30-16 06:03PM  Could Growing HIV Franchise Drive Gilead Sciences Valuation?
04:54PM  Prothena Builds On Psoriasis Science For Arthritis Treatment
02:37PM  Chardan Rates Regeneron A Sell, Advises Caution
11:52AM  Buy These 4 Stocks and Beat Biotech's Slump
11:10AM  Why Arrowhead Pharmaceuticals Stock Spiked Today at Motley Fool
10:15AM  Amgen (AMGN) Migraine Drug Hits Phase III Primary Endpoint
09:38AM  ETFs with exposure to Amgen, Inc. : September 30, 2016
Sep-29-16 11:21PM  Amgens Kyprolis Fails in Trial (AMGN) at Investopedia
05:39PM  Amgens Backup Plan for Kyprolis (AMGN) at Investopedia
05:16PM  [$$] Zymeworks Gains Immuno-Oncology Drugs Through Daiichi Sankyo Deal at The Wall Street Journal
05:06PM  Long Wait for Biosimilar Amjevita (AMGN) at Investopedia
04:40PM  Stocks skid as drugmakers fall, then bank woes deepen losses
04:29PM  Amgen Maintains Migraine Drug Lead (AMGN) at Investopedia
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy's Laboratories Ltd.; and Nuevolution AB. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM